Joseph Schoepfer

The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1

Andrew A. Wylie, Joseph Schoepfer, Wolfgang Jahnke et al. · Nature · 2017 · 574 citations

Molecular Pharmacology, Drug Target, Medicine +3

Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1

Joseph Schoepfer, Wolfgang Jahnke, Giuliano Berellini et al. · Journal of Medicinal Chemistry · 2018 · 432 citations · Full text

Drug Target, Mixed-phenotype Acute Leukemia, Molecular Biology +16

NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models

Michael Rugaard Jensen, Joseph Schoepfer, Thomas Radimerski et al. · Breast Cancer Research · 2008 · 222 citations · Full text

Discovery of a Potent and Selective Protein Kinase CK2 Inhibitor by High-Throughput Docking

Eric Vangrevelinghe, Kaspar Zimmermann, Joseph Schoepfer et al. · Journal of Medicinal Chemistry · 2003 · 215 citations

Molecular Docking, Medicinal Chemistry, Drug Target +15

Combining Hit Identification Strategies: Fragment-Based and in Silico Approaches to Orally Active 2-Aminothieno[2,3-<i>d</i>]pyrimidine Inhibitors of the Hsp90 Molecular Chaperone

Paul A. Brough, Xavier Barril, Jenifer Borgognoni et al. · Journal of Medicinal Chemistry · 2009 · 173 citations · Full text